Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia

Cancer

Volumn 115, Issue 20, 2009, Pages 4839-4848

  Heaney, Mark L ^a   Toy, Edmond L ^b   Vekeman, Francis ^c   Laliberté, François ^c   Dority, Bree L ^b   Perlman, Daniel ^b   Barghout, Victoria ^d   Mei, Sheng Duh ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Analysis Group Inc   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d Bayer HealthCare Pharmaceuticals Inc   (United States)

^e ANALYSIS GROUP   (United States)

Author keywords

Colony stimulating factors; Infection; Neutropenia; Treatment costs

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION COST; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COSTS; FEMALE; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RISK;

EID: 70350109377     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24535     Document Type: Article

References (29)

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228-237. (Pubitemid 38063629)
2. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003;1:23-35.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, V. 1.2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/myeloid-growth.pdf Accessed May 12, 2008.
4. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916-1924. (Pubitemid 40563265)
5. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-2266. (Pubitemid 43673249)
6. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187-3205. (Pubitemid 46638957)
7. Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 2003;97:186-200. (Pubitemid 36033878)
8. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using 4 melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026.
9. Ruttinger D, van den Engel NK, Winter H, et al. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med. 2007;5:43. (Pubitemid 47593394)
10. Jones SE, Schottstaedt MW, Duncan LA, et al. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol. 1996;14:2976-2983.
11. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112:406-411. (Pubitemid 34246271)
12. Yau JC, Neidhart JA, Triozzi P, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor support for dose-intensive cyclophosphamide, etoposide, and cisplatin. Am J Hematol. 1996;51:289-295. (Pubitemid 26117543)
13. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-324. (Pubitemid 23025731)
14. Milkovich G, Moleski RJ, Reitan JF, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy. 2000;20:1432-1440.
15. Wong SF, Chan HO. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Pharmacotherapy. 2005;25:372-378.
16. Beveridge RA, Miller JA, Kales AN, et al. Randomized trial comparing the tolerability of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer. 1997;5:289-298.
17. Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest. 1998;16:366-373. (Pubitemid 28355257)
18. Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm. 2005;62:83-87. (Pubitemid 40394640)
19. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-109; discussion 1081-1090.
20. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90:1205-1211. (Pubitemid 28407086)
21. Chrischelles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control. 2003;10:396-403. (Pubitemid 37296067)
22. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62(suppl 1):1-15.
23. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158-3167. (Pubitemid 47218066)
24. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178-1184.
25. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457-462.
26. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-1778.
27. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949-954.
28. Bennett C, Stinson T, Bhoopalam N, Marriott M, Panganiban J, Kozloff M. A double-blind, randomized trial of toxicity, resource use and costs for filgrastim and sargramostim [abstract]. Proc Am Soc Clin Oncol. 2000;19:437a. Abstract 1712.
29. Whalen CR, Watson TL, Baize T, Ball A. Formulary management of colony-stimulating factors. Am J Health Syst Pharm. 2002;59(7 suppl 2):S21-S27.